logo

Biomarin Pharmaceutical Inc. (BMRN)



Trade BMRN now with
  Date
  Headline
5/1/2020 4:39:02 PM Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) 2020 Estimate To 0.11 From 0.22
5/1/2020 4:36:47 PM Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) 2021 Rev. Estimate To 2073.0 M From 2098.7 M
5/1/2020 4:36:30 PM Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) 4Q21 Rev. Estimate To 536.4 M From 542.9 M
5/1/2020 4:36:14 PM Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) 3Q21 Rev. Estimate To 524.9 M From 531.3 M
5/1/2020 4:35:54 PM Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) 2Q21 Rev. Estimate To 509.6 M From 516.0 M
5/1/2020 4:35:32 PM Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) 1Q21 Rev. Estimate To 502.2 M From 508.6 M
5/1/2020 4:35:16 PM Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) 2020 Rev. Estimate To 1877.6 M From 1952.0 M
5/1/2020 4:34:42 PM Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) 4Q20 Rev. Estimate To 501.7 M From 524.5 M
5/1/2020 4:34:10 PM Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) 3Q20 Rev. Estimate To 478.5 M From 501.0 M
5/1/2020 4:33:43 PM Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) 2Q20 Rev. Estimate To 395.3 M From 474.0 M
4/29/2020 4:06:42 PM Biomarin Pharmaceutical Inc. (BMRN) Has Lowered Its FY20 Revenue Estimate To $1,850 - $1,950 Mln From $1,950 - $2,050 Mln
4/29/2020 4:04:26 PM BioMarin Q1 EPS $0.44 Vs. Loss $0.32 Year Ago
4/21/2020 8:32:14 AM BioMarin Appoints Greg Guyer To Chief Technical Officer, EVP Of Global Manufacturing And Technical Operations
4/6/2020 8:38:47 AM BioMarin Plans Regulatory Submissions For Marketing Authorization Of Vosoritide To FDA And EMA In Q3
2/26/2020 4:06:46 PM BioMarin Q4 GAAP EPS $0.08 Vs Loss $0.03 Last Year